<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>HB 450 (Edition 1)</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Times New \(W1\)";}
@font-face
	{font-family:IDAutomationHC39M;
	panose-1:2 0 5 9 0 0 0 2 0 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.25pt;
	margin-bottom:.0001pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:23.75pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.MsoLineNumber
	{font-family:"Times New Roman",serif;}
p.LMSBase, li.LMSBase, div.LMSBase
	{mso-style-name:LMSBase;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aArticle, li.aArticle, div.aArticle
	{mso-style-name:aArticle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aArticleTitle, li.aArticleTitle, div.aArticleTitle
	{mso-style-name:aArticleTitle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBase, li.aBase, div.aBase
	{mso-style-name:aBase;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBillSection, li.aBillSection, div.aBillSection
	{mso-style-name:aBillSection;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:.75in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock1, li.aBlock1, div.aBlock1
	{mso-style-name:aBlock1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock2, li.aBlock2, div.aBlock2
	{mso-style-name:aBlock2;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.75in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock3, li.aBlock3, div.aBlock3
	{mso-style-name:aBlock3;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock4, li.aBlock4, div.aBlock4
	{mso-style-name:aBlock4;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.75in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock5, li.aBlock5, div.aBlock5
	{mso-style-name:aBlock5;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aChapter, li.aChapter, div.aChapter
	{mso-style-name:aChapter;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.aHeading, li.aHeading, div.aHeading
	{mso-style-name:aHeading;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aLongTitle, li.aLongTitle, div.aLongTitle
	{mso-style-name:aLongTitle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New \(W1\)";
	text-transform:uppercase;}
p.aMargin1, li.aMargin1, div.aMargin1
	{mso-style-name:aMargin1;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aMargin2, li.aMargin2, div.aMargin2
	{mso-style-name:aMargin2;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:.75in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aPart, li.aPart, div.aPart
	{mso-style-name:aPart;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSection, li.aSection, div.aSection
	{mso-style-name:aSection;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.75in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.aSP, li.aSP, div.aSP
	{mso-style-name:aSP;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.aSPComment, li.aSPComment, div.aSPComment
	{mso-style-name:aSPComment;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New \(W1\)";
	color:red;
	display:none;
	font-weight:bold;}
p.aSPFunds1, li.aSPFunds1, div.aSPFunds1
	{mso-style-name:aSPFunds1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSPFunds2, li.aSPFunds2, div.aSPFunds2
	{mso-style-name:aSPFunds2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSPFundsHeading1, li.aSPFundsHeading1, div.aSPFundsHeading1
	{mso-style-name:aSPFundsHeading1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.aSPFundsHeading2, li.aSPFundsHeading2, div.aSPFundsHeading2
	{mso-style-name:aSPFundsHeading2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.aSPHeading, li.aSPHeading, div.aSPHeading
	{mso-style-name:aSPHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-1.0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.nonumber, li.nonumber, div.nonumber
	{mso-style-name:nonumber;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSPHeadingLine, li.aSPHeadingLine, div.aSPHeadingLine
	{mso-style-name:aSPHeadingLine;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.ASPlist, li.ASPlist, div.ASPlist
	{mso-style-name:ASPlist;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.5in;
	margin-bottom:.0001pt;
	text-indent:-1.75in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSPRequestedBY, li.aSPRequestedBY, div.aSPRequestedBY
	{mso-style-name:aSPRequestedBY;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New \(W1\)";}
p.aSPTitle, li.aSPTitle, div.aSPTitle
	{mso-style-name:aSPTitle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New \(W1\)";
	text-transform:uppercase;
	font-weight:bold;}
p.aSubChapter, li.aSubChapter, div.aSubChapter
	{mso-style-name:aSubChapter;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aSubPart, li.aSubPart, div.aSubPart
	{mso-style-name:aSubPart;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aTitle, li.aTitle, div.aTitle
	{mso-style-name:aTitle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.cHistoryNote
	{mso-style-name:cHistoryNote;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Times New Roman",serif;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Times New Roman",serif;}
p.TOCPageHeader, li.TOCPageHeader, div.TOCPageHeader
	{mso-style-name:TOCPageHeader;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aSPSubTitle, li.aSPSubTitle, div.aSPSubTitle
	{mso-style-name:aSPSubTitle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aSPHeadingMiscellaneous, li.aSPHeadingMiscellaneous, div.aSPHeadingMiscellaneous
	{mso-style-name:aSPHeadingMiscellaneous;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-1.0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aDistrict, li.aDistrict, div.aDistrict
	{mso-style-name:aDistrict;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
.MsoChpDefault
	{font-family:"Calibri",sans-serif;}
.MsoPapDefault
	{margin-bottom:10.0pt;
	line-height:115%;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 11.0in;
	margin:.6in .9in .5in 1.2in;}
div.WordSection1
	{page:WordSection1;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=nonumber align=center style='margin-top:24.0pt;text-align:center'><b>GENERAL
ASSEMBLY OF NORTH CAROLINA</b></p>

<p class=nonumber align=center style='margin-top:3.0pt;margin-right:0in;
margin-bottom:6.0pt;margin-left:0in;text-align:center'><b>SESSION 2019</b></p>

<p class=nonumber align=left style='text-align:left'><b>H                                                                                                                                                    1</b></p>

<p class=nonumber align=center style='text-align:center'><b>HOUSE BILL 450</b></p>

<p class=nonumber align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=nonumber align=center style='text-align:center'><b>&nbsp;</b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=0
 style='width:6.55in;margin-left:-5.75pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=527 colspan=2 valign=top style='width:395.25pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in .05in 0in 5.4pt'>
  <p class=nonumber align=left style='margin-bottom:6.0pt;text-align:left'>Short
  Title:      Reduce Barriers to Improve NC Health &amp; Safety.</p>
  </td>
  <td width=102 valign=top style='width:76.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in .05in 0in 5.4pt'>
  <p class=nonumber align=right style='margin-bottom:6.0pt;text-align:right'>(Public)</p>
  </td>
 </tr>
 <tr>
  <td width=96 valign=top style='width:71.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in .05in 0in 5.4pt'>
  <p class=nonumber align=left style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:left'>Sponsors:</p>
  </td>
  <td width=533 colspan=2 valign=top style='width:399.75pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in .05in 0in 5.4pt'>
  <p class=nonumber align=left style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:left'>Representatives Potts,
  Dobson, Lewis, and Sasser (Primary Sponsors).</p>
  <p class=nonumber align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:center'><i><span
  style='font-size:10.0pt'>For a complete list of sponsors, refer to the North
  Carolina General Assembly web site.</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=96 valign=top style='width:71.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in .05in 0in 5.4pt'>
  <p class=nonumber align=left style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:left'>Referred to:</p>
  </td>
  <td width=533 colspan=2 valign=top style='width:399.75pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in .05in 0in 5.4pt'>
  <p class=nonumber style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  3.0pt;margin-left:0in'>Health, if favorable, Rules, Calendar, and Operations
  of the House</p>
  </td>
 </tr>
 <tr height=0>
  <td width=96 style='border:none'></td>
  <td width=431 style='border:none'></td>
  <td width=102 style='border:none'></td>
 </tr>
</table>

<p class=nonumber align=center style='margin-top:6.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center'>March 27, 2019</p>

<p class=aBase align=center style='text-align:center'><span style='color:black'>A
BILL TO BE ENTITLED</span></p>

<p class=aLongTitle><span style='font-family:"Times New Roman",serif;
color:black'>AN ACT to increase access to abuse&#8209;deterrent opioid
analgesics and to ensure the proper administration of step therapy protocols
for prescription drugs.</span></p>

<p class=aMargin2><span style='color:black'>Whereas, opioid&#8209;related
deaths have doubled in North Carolina between 1999 and 2013; and</span></p>

<p class=aMargin2><span style='color:black'>Whereas, a 2013 National Survey on
Drug Use and Health found that over 63% of all people who abuse prescription
drugs obtained the drugs from family and friends; and</span></p>

<p class=aMargin2><span style='color:black'>Whereas, opioid abuse in North
Carolina is a serious and severe problem that affects the health, social, and
economic welfare of this State; and</span></p>

<p class=aMargin2><span style='color:black'>Whereas, abuse&#8209;deterrent
opioid analgesics have been labelled a top priority by the United States Food
and Drug Administration; and</span></p>

<p class=aMargin2><span style='color:black'>Whereas, patient access to abuse&#8209;deterrent
opioid analgesics is an important step in addressing the opioid abuse epidemic;
and</span></p>

<p class=aMargin2><span style='color:black'>Whereas, health benefit plans are
increasingly making use of step therapy protocols under which patients are
required to try one or more prescription drugs before coverage is provided for a
drug selected by the patient's health care provider; and</span></p>

<p class=aMargin2><span style='color:black'>Whereas, when step therapy
protocols are based on well&#8209;developed scientific standards and
administered in a flexible manner that takes into account the individual needs
of patients, the protocols can play an important role in controlling health
care costs; and</span></p>

<p class=aMargin2><span style='color:black'>Whereas, in some cases, requiring a
patient to follow a step therapy protocol may have adverse and even dangerous
consequences for the patient who may either not realize a benefit from taking a
prescription drug or may suffer harm from taking an inappropriate drug; and</span></p>

<p class=aMargin2><span style='color:black'>Whereas, without uniform policies
in the State for step therapy protocols, patients may not receive the best and
most appropriate treatment; and</span></p>

<p class=aMargin2><span style='color:black'>Whereas, it is imperative that step
therapy protocols preserve the health care provider's right to make treatment
decisions in the best interest of the patient; and</span></p>

<p class=aMargin2><span style='color:black'>Whereas, the General Assembly
declares it a matter of public interest that it require health benefit plans
base step therapy protocols on appropriate clinical practice guidelines
developed by independent experts with knowledge of the condition or conditions
under consideration; that patients be exempt from step therapy protocols when
inappropriate or otherwise not in the best interest of the patients; and that
patients have access to a fair, transparent, and independent process for
requesting an exception to a step therapy protocol when appropriate; Now,
therefore,</span></p>

<p class=aBase><span style='color:black'>The General Assembly of North Carolina
enacts:</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 1.</span></b><span
style='color:black'>  Article 3 of Chapter 58 of the General Statutes is
amended by adding a new section to read:</span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 58&#8209;3&#8209;295.  Coverage for abuse&#8209;deterrent
opioid analgesics.</span></u></p>

<p class=aMargin1><u><span style='color:black'>(a)</span></u><span
style='color:black'>        <u>The following definitions apply in this section:</u></span></p>

<p class=aBlock1><u><span style='color:black'>(1)</span></u><span
style='color:black'>        <u>Abuse&#8209;deterrent opioid analgesic drug
product. – A brand or generic opioid analgesic drug product approved by the
United States Food and Drug Administration with an abuse&#8209;deterrence
labeling claim that indicates that the drug product is expected to deter abuse.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(2)</span></u><span
style='color:black'>        <u>Opioid analgesic drug product. – A drug product
in the opioid analgesic drug class prescribed to treat moderate to severe pain
or other conditions in immediate&#8209;release, extended&#8209;release, or long&#8209;acting
form, regardless of whether or not combined with other drug substances to form
a single drug product or dosage form.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(b)</span></u><span
style='color:black'>        <u>Any health benefit plan that provides coverage
for abuse&#8209;deterrent opioid analgesic drug products may impose a prior
authorization requirement for an abuse&#8209;deterrent opioid analgesic drug
product only if the health benefit plan imposes the same prior authorization
requirement for each opioid analgesic drug product without an abuse&#8209;deterrence
labeling claim.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(c)</span></u><span
style='color:black'>        <u>No health benefit plan that provides coverage
for abuse&#8209;deterrent opioid analgesic drug products may require the use of
an opioid analgesic drug product without an abuse&#8209;deterrence labeling
claim before authorizing the use of an abuse&#8209;deterrent opioid analgesic
drug product.</u>&quot;</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 2.</span></b><span
style='color:black'>  Article 50 of Chapter 58 of the General Statutes is
amended by adding a new Part to read:</span></p>

<p class=aPart><span style='color:black'>&quot;<u>Part 8. Administration of
Step Therapy Protocols.</u></span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 58&#8209;50&#8209;305.  Definitions.</span></u></p>

<p class=aMargin1><u><span style='color:black'>As used in this Article, unless
the context clearly requires otherwise, the following definitions apply:</span></u></p>

<p class=aBlock1><u><span style='color:black'>(1)</span></u><span
style='color:black'>        <u>Clinical practice guidelines. – A systematically
developed statement to assist health care provider and patient decisions about
appropriate health care for specific clinical circumstances and conditions.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(2)</span></u><span
style='color:black'>        <u>Clinical review criteria. – The written
screening procedures, decision abstracts, clinical protocols, and practice
guidelines used by an insurer, health plan, or utilization review organization
to determine the medical necessity and appropriateness of health care services.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(3)</span></u><span
style='color:black'>        <u>Step therapy override determination. – A
determination as to whether a step therapy protocol should apply in a
particular situation or whether the step therapy protocol should be overridden
in favor of immediate coverage of the health care provider's selected
prescription drug. This determination is based on a review of the patient's or
prescriber's request for an override along with supporting rationale and
documentation.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(4)</span></u><span
style='color:black'>        <u>Step therapy protocol. – A protocol or program
that establishes the specific sequence in which prescription drugs for a
specified medical condition are medically appropriate for a particular patient and
are covered by an insurer or health plan.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(5)</span></u><span
style='color:black'>        <u>Utilization review organization. – As defined in
G.S.&nbsp;58&#8209;50&#8209;61(a)(18).</u></span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 58&#8209;50&#8209;310.  Clinical review criteria.</span></u></p>

<p class=aMargin1><u><span style='color:black'>Clinical review criteria used to
establish a step therapy protocol shall be based on clinical practice
guidelines that meet all of the following requirements:</span></u></p>

<p class=aBlock1><u><span style='color:black'>(1)</span></u><span
style='color:black'>        <u>Recommend that the prescription drugs be taken
in the specific sequence required by the step therapy protocol.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(2)</span></u><span
style='color:black'>        <u>Are developed and endorsed by an independent,
multidisciplinary panel of experts not affiliated with a health benefit plan or
utilization review organization.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(3)</span></u><span
style='color:black'>        <u>Are based on high&#8209;quality studies,
research, and medical practice.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(4)</span></u><span
style='color:black'>        <u>Are created by an explicit and transparent
process that includes all of the following:</u></span></p>

<p class=aBlock2><u><span style='color:black'>a.</span></u><span
style='color:black'>         <u>Minimizes biases and conflicts of interest.</u></span></p>

<p class=aBlock2><u><span style='color:black'>b.</span></u><span
style='color:black'>         <u>Explains the relationship between treatment
options and outcomes.</u></span></p>

<p class=aBlock2><u><span style='color:black'>c.</span></u><span
style='color:black'>         <u>Rates the quality of the evidence supporting
recommendations.</u></span></p>

<p class=aBlock2><u><span style='color:black'>d.</span></u><span
style='color:black'>         <u>Considers relevant patient subgroups and
preferences.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(5)</span></u><span
style='color:black'>        <u>Are continually updated through a review of new
evidence and research.</u></span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 58&#8209;50&#8209;315.  Exceptions process transparency.</span></u></p>

<p class=aMargin1><u><span style='color:black'>(a)</span></u><span
style='color:black'>        <u>Exceptions Process. – When coverage of a
prescription drug for the treatment of any medical condition is restricted for
use by a health benefit plan or utilization review organization through the use
of a step therapy protocol, the patient and prescribing practitioner shall have
access to a clear and convenient process to request a step therapy override
determination. A health benefit plan or utilization review organization may use
its existing medical exceptions process to satisfy this requirement. The
process shall be made easily accessible on the health benefit plan's or
utilization review organization's Web site.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(b)</span></u><span
style='color:black'>        <u>Exceptions. – A step therapy override
determination request shall be expeditiously granted if any of the following
apply:</u></span></p>

<p class=aBlock1><u><span style='color:black'>(1)</span></u><span
style='color:black'>        <u>The required prescription drug is contraindicated
or will likely cause an adverse reaction or physical or mental harm to the
patient.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(2)</span></u><span
style='color:black'>        <u>The required prescription drug is expected to be
ineffective based on the known relevant physical or mental characteristics of
the patient and the known characteristics of the prescription drug regimen.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(3)</span></u><span
style='color:black'>        <u>The patient has tried the required prescription
drug while under their current or a previous health insurance or health benefit
plan or another prescription drug in the same pharmacologic class or with the
same mechanism of action and such prescription drug was discontinued due to
lack of efficacy or effectiveness, diminished effect, or an adverse event.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(4)</span></u><span
style='color:black'>        <u>The required prescription drug is not in the
best interest of the patient, based on medical appropriateness.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(5)</span></u><span
style='color:black'>        <u>The patient is stable on a prescription drug
selected by their health care provider for the medical condition under
consideration.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(c)</span></u><span
style='color:black'>        <u>Effect of Exception. – Upon the granting of a
step therapy override determination, the health benefit plan or utilization
review organization shall authorize coverage for the prescription drug
prescribed by the patient's treating health care provider, provided such
prescription drug is a covered prescription drug under such policy or contract.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(d)</span></u><span
style='color:black'>       <u>Response to Exception Requests and Appeals. – The
health benefit plan or utilization review organization shall respond to a step
therapy exception request or an appeal of a step therapy exception request
denial within 72 hours of receipt of the request or appeal. In cases where
exigent circumstances exist, the health benefit plan or utilization review
organization shall respond within 24 hours of receipt of a step therapy
exception request or an appeal. If the health benefit plan or utilization
review organization does not respond to the request or appeal within the time required
by this subsection, then the exception request or the appeal shall be deemed
granted.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(e)</span></u><span
style='color:black'>        <u>Limitations. – This section shall not be
construed to prevent any of the following:</u></span></p>

<p class=aBlock1><u><span style='color:black'>(1)</span></u><span
style='color:black'>        <u>A health benefit plan or utilization review
organization from requiring a patient to try an AB&#8209;rated generic
equivalent prior to providing coverage for the equivalent branded prescription
drug.</u></span></p>

<p class=aBlock1><u><span style='color:black'>(2)</span></u><span
style='color:black'>        <u>A health care provider from prescribing a
prescription drug that is determined to be medically appropriate.</u></span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><u><span
style='color:black'>§ 58&#8209;50&#8209;320.  Rules and limitation of Part.</span></u></p>

<p class=aMargin1><u><span style='color:black'>(a)</span></u><span
style='color:black'>        <u>The Commissioner shall adopt rules to implement
this Article.</u></span></p>

<p class=aMargin1><u><span style='color:black'>(b)</span></u><span
style='color:black'>        <u>Nothing in this Part shall be construed to
impact an insurer's ability to substitute a generic drug for a name brand drug.</u>&quot;</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 3.</span></b><span
style='color:black'>  This act becomes effective October 1, 2019, and applies
to insurance contracts issued, renewed, or amended on or after that date.</span></p>

</div>

</body>

</html>
